Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine

被引:183
作者
Gothelf, D
Falk, B
Singer, P
Kairi, M
Phillip, M
Zigel, L
Poraz, I
Frishman, S
Constantini, N
Zalsman, G
Weizman, A
Apter, A
机构
[1] Schneider Childrens Med Ctr Israel, Richard E Feinberg Dept Psychiat, Feinberg Child Study Ctr, Behav Genet Clin, IL-49202 Petah Tiqwa, Israel
[2] Wingate Inst Phys Educ & Sports, Ribstein Ctr Sport Med & Res, Netanya, Israel
[3] Tel Aviv Med Sch, Geha Psychiat Ctr, Tel Aviv, Israel
关键词
D O I
10.1176/appi.ajp.159.6.1055
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective: The authors studied weight gain mechanisms and energy balance in patients treated with olanzapine. Method: The body mass index of male schizophrenic adolescent inpatients treated with olanzapine (N=10) and of 10 matched patients treated with haloperidol (N=10) were measured at baseline and after 4 weeks of treatment. For the patients treated with olanzapine, caloric intake, resting energy expenditure, and physical activity (determined through accelerometry and heart rate monitoring) were assessed at baseline and after 4 weeks of treatment. Results: Body mass index significantly increased in those treated with olanzapine but not in those given haloperidol. The increase in body mass index was due to an increase in caloric intake without change in diet composition. olanzapine had no significant effect on resting energy expenditure. Daily energy expenditure was very low before and after treatment. Conclusions: Olanzapine-induced weight gain is associated with a general increase in caloric intake.
引用
收藏
页码:1055 / 1057
页数:3
相关论文
共 10 条
[1]  
Allison DB, 1999, AM J PSYCHIAT, V156, P1686
[2]   PSYCHOMETRIC PROPERTIES OF THE K-SADS-P IN AN ISRAELI ADOLESCENT INPATIENT POPULATION [J].
APTER, A ;
ORVASCHEL, H ;
LASEG, M ;
MOSES, T ;
TYANO, S .
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 1989, 28 (01) :61-65
[3]   Body weight gain induced by antipsychotic drugs: mechanisms and management [J].
Baptista, T .
ACTA PSYCHIATRICA SCANDINAVICA, 1999, 100 (01) :3-16
[4]  
BERNSTEIN JG, 1988, CLIN NEUROPHARMACOL, V11, pS194
[5]  
*CDCP, 2001, CDC GROWTH CHARTS US
[6]   Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months [J].
Kelly, DL ;
Conley, RR ;
Love, RC ;
Horn, DS ;
Ushchak, CM .
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 1998, 8 (03) :151-159
[7]   Risperidone-associated weight gain in children and adolescents: A retrospective chart review [J].
Martin, A ;
Landau, J ;
Leebens, P ;
Ulizio, K ;
Cicchetti, D ;
Scahill, L ;
Leckman, JF .
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2000, 10 (04) :259-268
[8]   Weight gain associated with olanzapine and risperidone in adolescent patients: A comparative prospective study [J].
Ratzoni, G ;
Gothelf, D ;
Brand-Gothelf, A ;
Reidman, J ;
Kikinzon, L ;
Gal, G ;
Phillip, M ;
Apter, A ;
Weizman, R .
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2002, 41 (03) :337-343
[9]   WEIGHT-GAIN ASSOCIATED WITH NEUROLEPTIC MEDICATION - A REVIEW [J].
STANTON, JM .
SCHIZOPHRENIA BULLETIN, 1995, 21 (03) :463-472
[10]   Using objective physical activity measures with youth: How many days of monitoring are needed? [J].
Trost, SG ;
Pate, RR ;
Freedson, PS ;
Sallis, JF ;
Taylor, WC .
MEDICINE AND SCIENCE IN SPORTS AND EXERCISE, 2000, 32 (02) :426-431